Becton, Dickinson and Company(又稱 BD)是一家美國跨國醫療技術公司,製造及銷售醫療器械、儀器系統和試劑。BD 亦在某些地區提供諮詢和分析服務。
財務指標
營業收入
2026-06-30
$4.98B
2026-03-31
$4.71B
2025-12-31
$5.25B
2025-09-30
$5.89B
營業支出
2026-06-30
$1.65B
2026-03-31
$2.06B
2025-12-31
$1.75B
2025-09-30
$2.1B
淨利潤
2026-06-30
$377M
2026-03-31
-$311M
2025-12-31
$382M
2025-09-30
$493M
淨利潤率
2026-06-30
7.56%
2026-03-31
-6.59%
2025-12-31
7.27%
2025-09-30
8.37%
每股收益
2026-06-30
$3.23
2026-03-31
$2.90
2025-12-31
$2.91
2025-09-30
$3.96
息稅折舊攤銷前利潤
2026-06-30
$1.24B
2026-03-31
$709M
2025-12-31
$1.2B
2025-09-30
$1.29B
有效稅率
2026-06-30
18.59%
2026-03-31
194.87%
2025-12-31
21.56%
2025-09-30
3.33%
項目
2026-06-30
2026-03-31
2025-12-31
2025-09-30
營業收入
$4.98B
$4.71B
$5.25B
$5.89B
營業支出
$1.65B
$2.06B
$1.75B
$2.1B
淨利潤
$377M
-$311M
$382M
$493M
淨利潤率
7.56%
-6.59%
7.27%
8.37%
每股收益
$3.23
$2.90
$2.91
$3.96
息稅折舊攤銷前利潤
$1.24B
$709M
$1.2B
$1.29B
有效稅率
18.59%
194.87%
21.56%
3.33%
常見問題
BDX is the ticker symbol for Becton, Dickinson and Company, often referred to as BD. Founded in 1897, it is a global medical technology company that develops and sells a wide range of medical devices, instrument systems, and reagents. BD serves healthcare institutions, life science researchers, clinical laboratories, and the general public. Its operations are divided into segments such as BD Medical, BD Life Sciences, and BD Interventional, making it a key player in the healthcare sector.
Recent performance for BDX can be found in the stock price section of this page, which displays the latest price, daily change, and trading volume. Performance often reflects investor reactions to quarterly earnings, product announcements, or broader market trends. For a complete view, compare the current price to the 52-week high and low also shown on the page. Historical price charts and returns over various periods are available in the performance data displayed.
Valuation of BDX can be assessed using metrics such as the price-to-earnings (P/E) ratio, price-to-sales (P/S), and enterprise value-to-EBITDA (EV/EBITDA). These are typically compared to BD's own historical averages and to peers in the medical technology industry. Other factors include expected earnings growth, profit margins, and return on equity. The current valuation metrics for BDX are provided in the valuation section of this page, allowing you to see how the market is pricing the stock relative to its fundamentals.
BDX shares can be traded in pre-market and after-hours sessions on U.S. exchanges, though liquidity is often lower and spreads may be wider than during regular trading hours. These extended sessions allow investors to react to news released outside of standard market times. However, not all brokers offer extended-hours trading, and order types may be limited. Check with your brokerage for specific availability and any associated fees or restrictions for trading BDX outside regular hours.
Yes, Becton, Dickinson and Company has a long history of paying dividends to shareholders. The company has consistently returned cash to investors through quarterly dividend payments. The current dividend amount, yield, and payment schedule are available in the dividend section of this page. Investors often consider BDX as a dividend-paying stock within the healthcare sector, though dividend policies can change based on company performance and strategic priorities.
Key risks for BDX include regulatory changes in healthcare, product liability, intense competition, and dependence on new product approvals. Economic downturns can reduce hospital spending, affecting sales. Currency fluctuations impact international revenue, and supply chain disruptions may affect manufacturing. Additionally, changes in reimbursement policies and patent expirations pose challenges. Investors should review BDX's risk factors in its annual report (Form 10-K) and consider how these risks might affect future performance.